期刊文献+

反应停的抗肿瘤作用机制及临床应用 被引量:4

Anti-tumor Effects of Thalidomide and its Clinical Application
下载PDF
导出
摘要 新生血管生成在肿瘤的发生、发展及转移中起重要作用,且抗血管生成治疗取得了令人满意的效果。抗血管生成药物的研究得到人们的关注。反应停在20世纪50年代曾作为镇静药、止吐药使用,因其有很强的致畸作用而被市场淘汰,后发现其有免疫调节作用被用于治疗麻风、红斑狼疮、宿主抗移植物排斥反应等。随后的研究认为,其致畸作用可能与抗血管生成有关,从而用于治疗实体瘤及血液系统肿瘤。本文就反应停的抗肿瘤作用研究进展作一综述。 Angiogenasis has an important role during the occurrence, development and metastasis of tumor. Antiangiogenic therapy has achieved satisfactory effects. The research of drugs about antiangiogenesis have been noted. Thalidomide was used as a sedative and antiemetie in the 1950s,then removed from markets for its severe side effects of teratogenasis. Its immunoloregulation effects was then discovered, which was used in the therapy of leprosy, erythematoans lupus and graft-versus-host reaction. Subsequent researches showed that its teratogenesis was possibly related to its antiangiogenesis,so it was used in the therapy of solid tumors and malignant hematological di sceses. This article reviews thalidomide about its anti-tumor effect..
出处 《医学综述》 2007年第3期200-202,共3页 Medical Recapitulate
关键词 反应停 血管新生 肿瘤 Thalidomide Angiogenesis Neoplasm
  • 相关文献

参考文献20

  • 1D'Amato RJ,Loughnan MS,Flynn E,et al.Thalidomide is an inhibitor of angiogenesis[J].Proc Natl Acad Sci USA,1994,91 (9):4082-4085.
  • 2Kerst JM,Bex A,Mallo H,et al.Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiothetapy to bone and/or soft tissue metastasis:a phase Ⅱ study[J].Cancer Immunol Immunother,2005,54(9):926-931.
  • 3Dmoszynska A,Podhorecka M,Manko J,et al.The influence of thalidomide therapy on cytokine secretion,immunophenotype,BCL-2 expression and microvessel density in patients with resistant or relapsed multiple myeloma[J].Neoplasm,2005,52(2):175-181.
  • 4Invernizzi R,Travaglino E,De Amici M,et al.Thalidomide treatment reduces apoptosis levels in bone marrow cells from patients with myelodysplastic syndromes[J].Leukemia Res,2005,29 (6):641-647.
  • 5Grzasko N,Dmoszynska A,Hus M,et al.Stimulation of erythropoiesis by thalidomide in multiple myeloma patients:its influence on FasL,TRAIL and their receptors on erythroblasts[J].Haematologica,2006,91(3):386-389.
  • 6Settles B,Stevenson A,Wilson K.Down-regulation of cell adhesion molecules LFA-1 and ICAM -1 after in vitro treatment with the antiTNF-alpha agent thalidomide[J].Cell Mol Biol (Noisy-le-grand),2001,47(7):1105-1114.
  • 7Glasmacher A,Hahn C,Hoffmann F,et al.A systematic review of phase-Ⅱ trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma[J].Br J Haematol,2006,132 (5):584-593.
  • 8Rajkumar SV,Blood E,Vesole D,Fonseca R,et al.Phase Ⅲ clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma:a clinical trial coordinated by the Eastern Cooperative Oncology Group[J].J Clin Oncol,2006,24(3):431-436.
  • 9Palumbo A,Bringhen S,Caravita T,et al.Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma:randomized controlled trial[J].Lancet,2006,367(9513):825-831.
  • 10Kaufmann H,Raderer M,Wohrer S,et al.Anti-tumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma[J].Blood,2004,104(8):2269-2271.

二级参考文献6

  • 1Singtml S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refiractory multiple myeloma. N Engl J Med, 1999,341 : 1565-1571.
  • 2Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol, 1994,87:503-508.
  • 3Aguayo A, Estey E, Kantarjian H, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood, 1999,94:3717-3721.
  • 4Bellamy WT, Richter L, Sirjani D, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia proenitor formation in myelodysplastic syndromes. Blood, 2001,97:1427-1434.
  • 5Aguayo A, Kantarjian H, Manshouri T, et al. Angiosenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood, 2000,96:2240-2245,2367-2644.
  • 6王全顺,周绮,于力,达万明,楼方定.环孢素A联合化疗方案治疗复发、难治性白血病[J].白血病.淋巴瘤,2002,11(1):18-20. 被引量:9

共引文献8

同被引文献31

引证文献4

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部